Raymond James & Associates Zentalis Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 15,865 shares of ZNTL stock, worth $35,220. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,865
Previous 11,239
41.16%
Holding current value
$35,220
Previous $45,000
28.89%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
68MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$31 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$19 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$10.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$10.2 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$6.9 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $127M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...